Additional drug treatment approved for heart patientsBMJ 2001; 323 doi: https://doi.org/10.1136/bmj.323.7326.1388d (Published 15 December 2001) Cite this as: BMJ 2001;323:1388
- Scott Gottlieb
- New York
Adding the angiotensin II receptor blocker valsartan to prescribed treatment for patients with heart failure significantly reduces morbidity and admission to hospital, final results of the valsartan heart failure trial (Val-HeFT) have shown.
Valsartan was not effective, however, in patients who also received both b blockers and angiotensin converting enzyme (ACE) inhibitors.
In the study, Dr Jay Cohn from the University of Minnesota Medical School in Minneapolis, Dr Gianni Tognoni from the Mario Negri Institute in Milan, and colleagues from the valsartan heart failure trial randomly assigned 5010 patients with class II to IV heart …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial